Kontracepcija i hormonsko nadomjesno liječenje s estetrolom

master's thesis

• Title (english): Contraception and hormone replacement therapy with estetrol
• Author: Tina Stanković
• Mentor: Dinka Pavičić Baldani (mentor)
• Committee member: Lana Škrgatić (predsjednik povjerenstva)
• Committee member: Marina Šprem Goldštajn (član povjerenstva)
• Committee member: Dinka Pavičić Baldani (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Gynecology and Obstetrics); Zagreb
• Defense date and country: 2022-07-15, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Gynecology and Obstetrics

Abstract

Obzirom na neupitne dobrobiti hormonskog nadomjesnog liječenja i oralne hormonske kontracepcije, postoji klinička potreba za uvođenjem novih estrogenskih formulacija koje imaju manji rizik nastanka venskih tromboembolija i manji utjecaj na proliferaciju tkiva dojke. Prikupljeni podaci iz provedenih pretkliničkih i kliničkih istraživanja podupiru estetrol kao obećavajući prirodni estrogen koji bi ispunio navedena očekivanja. Oralni kontraceptivi koji sadrže kombinaciju estetrola i drospirenona pokazali su bolju prihvaćenost i tolerabilnost među korisnicama u odnosu na oralne kontraceptive koji sadrže etinil estradiol kao estrogensku sastavnicu. E4/ DRSP učinkovito inhibira ovulaciju te pokazuje obećavajuće rezultate po pitanju obrazaca krvarenja i kontrole menstruacijskog ciklusa. Navedena kombinacija hormona također ima poželjan dobrobitni učinak na lipidni profil, jetru, razinu SHBG te metabolizam ugljikohidrata. Sukladno takvim učincima, ovaj steroidni hormon postaje preferirana opcija zbog smanjenog rizika za kardiovaskularne događaje poput duboke venske tromboze. Također, provedena su istraživanja dovela do zaključka da E4 zbog svog neutralnog učinka na tkivo dojke pruža siguran terapijski prozor za ubažavanje simptoma menopauze, bez stvaranja dodatnog rizika za razvoj karcinoma dojke.

Abstract (english)

Given the unquestionable benefits of hormone replacement therapy and oral hormone contraception, there is a clinical need to introduce new estrogen formulations that carry fewer venous thromboembolic risks and have less impact on breast tissue proliferation. The data collected from preclinical and clinical studies support estetrol as a promising natural estrogen that would meet these expectations.
Oral contraceptives containing a combination of estetrol and drospirenone have shown better acceptance and tolerance among users, compared to oral contraceptives containing ethinyl estradiol as an estrogenic component. E4 / DRSP effectively inhibits ovulation and shows promising results in terms of bleeding pattern and menstrual cycle control. This combination of hormones also has the desired effect on lipid profile, liver, SHBG levels and carbohydrate metabolism. Consistent with such effects, this steroid hormone is becoming the preferred option due to the reduced risk of cardiovascular incidents such as deep vein thrombosis. Also, the research has led to the conclusion that E4, due to its neutral effect on breast tissue, provides a safe therapeutic window for alleviating menopausal symptoms, without creating an additional risk for the development of breast tumors.

• Keywords: kontracepcija; hormonsko nadomjesno liječenje; estetrol
• Keywords (english): contraception; hormone replacement therapy; estetrol
• Language: croatian
• URN:NBN: urn:nbn:hr:105:132425
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-02-24 13:25:18